Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes



Status:Recruiting
Conditions:Colorectal Cancer, Colorectal Cancer, Cancer, Gastrointestinal
Therapuetic Areas:Gastroenterology, Oncology
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:July 2014
End Date:August 2021
Contact:Julie Starr
Email:jstarr@mail.med.upenn.edu
Phone:(215) 349 - 8527

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
This is an observational, case-control study evaluating the quantitative level of Septin9 in
plasma pre- and post-colectomy in hereditary colorectal cancer (CRC) syndrome patients
(Familial Adenomatous Polyposis (FAP), Lynch syndrome (also known as HNPCC), and Multiple
Adenomatous Polyposis (MAP, also known as MYK/MYH) cases) and genetically related FAP-family
members as controls and references.


Inclusion Criteria:

- Informed consent provided

- Age > or = to 18 years of age

- Patient group FAP

- Clinical diagnosis of familial adenomatous polyposis

- Patient group Lynch syndrome Clinical diagnosis of Lynch syndrome

- Patient group MAP

- Clinical diagnosis of MYH-associated polyposis and presence of more than 20 colon
polyps

- Control group (FAP)

- Genetically related family member of patient

- Patients: Able and willing to attend routine follow-up as advised

- Controls, i.e. relatives of patients: Willingness to give blood at each routine
follow-up as advised for the diseased relative

Exclusion Criteria:

- Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or
Hepatitis C Virus (HCV)

- Current diagnosis of colorectal cancer

- Pregnancy
We found this trial at
1
site
Univ of Pennsylvania
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Principal Investigator: Anil K. Rustgi, MD
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials